Country: Singapore
Language: English
Source: HSA (Health Sciences Authority)
Docetaxel
SANDOZ SINGAPORE PTE. LTD.
L01CD02
10mg/ml
INJECTION, SOLUTION, CONCENTRATE
Docetaxel 10mg/ml
INTRAVENOUS
Prescription Only
Fareva Unterach GmbH
ACTIVE
2014-06-25
Page 1 of 36 1. NAME OF THE MEDICINAL PRODUCT Docetaxel Sandoz Concentrate for Solution for Infusion 10 mg/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of the concentrate for solution for infusion contains 10 mg docetaxel. Each vial of 2 ml contains 20 mg docetaxel anhydrous (10 mg/ml). Each vial of 8 ml contains 80 mg docetaxel anhydrous (10 mg/ml). Each vial of 16 ml contains 160 mg docetaxel anhydrous (10mg/ml). Excipient: Each single-dose vial of concentrate for solution contains 27% (w/w) ethanol 96% _. _ _ _ _For a full list of excipients, see section 6.1. _ 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless to pale _, _ yellow solution; pH 3.0 - 4.5. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Breast cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast carcinoma. Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with • operable node-positive breast cancer • operable node-negative breast cancer For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer (see section 5.1). Non-small cell lung cancer Docetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer. Ovarian cancer Docetaxel is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. Prostate cancer Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer. Gastric adenocarcinoma Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not rece Read the complete document